调控纳米载体和肿瘤相关巨噬细胞用于肿瘤免疫治疗的研究进展  

Research Progress on Application of Nanocarriers and Tumor-associated Macrophages in Tumor Immunotherapy

作　　者：董婧 邹宏岩 陈静 姜颖[1,2] 孙夕林 吴丽娜[1,2] DONG Jing;ZOU Hong-yan;CHEN Jing;JIANG Ying;SUN Xi-lin;WU Li-na(The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150028,China;NHC and CAMS Key Laboratory of Probe and Targeted Theranostics,Molecular Imaging Research Center,Harbin Medical University,Harbin 150028,China)

机构地区：[1]哈尔滨医科大学附属第四医院,黑龙江哈尔滨150028 [2]哈尔滨医科大学分子影像研究中心,黑龙江哈尔滨150028

出　　处：《中国肿瘤》2021年第9期689-694,共6页China Cancer

基　　金：国家自然科学基金(81771903,81627901);中央支持地方高校改革发展基金优秀青年人才项目(2020YQ04)。

摘　　要：巨噬细胞是维持机体内环境稳定、抵御外来病原体的重要先天免疫群体,具有较高的可塑性。在肿瘤局部趋化因子的作用下,浸润到肿瘤组织中的巨噬细胞被称为肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs),其通过调控基质重构、新生血管生成和抑制局部免疫等方式促进肿瘤生长和转移。研究发现,针对TAMs的治疗均显示出良好的抗肿瘤作用,包括清除TAMs、诱导TAMs表型改变以及提高TAMs的吞噬能力等。纳米载体在提高药物溶解度、生物相容性和治疗效果方面均表现出了良好的潜力。将纳米技术与癌症免疫治疗结合是一种极具前景的肿瘤治疗方法。该文将对上述研究成果进行综述,为有效治疗肿瘤提供新视角。Macrophages are important innate immune cells that maintain the stability of internal environment and resist foreign pathogens in human body. Tumor-associated macrophages(TAMs) are macrophages infiltrating in tumor tissue, which promote tumor growth and metastasis through matrix remodeling, neoangiogenesis, and suppressing local immunity. Cancer immunotherapies targeting TAMs have shown great progress, which inhibit macrophage recruitment, deplete TAMs, reprogram TAMs and enhance phagocytic ability of macrophages. Nanodrug delivery systems have shown great potential in improving drug solubility, biocompatibility and therapeutic efficacy. Combining nanotechnology with cancer immunotherapy is a promising approach for cancer treatment. These aspects are discussed in this review which provides a novel direction for cancer treatment.

关 键 词：巨噬细胞 肿瘤相关巨噬细胞 免疫治疗 纳米载体 

分 类 号：R730.51[医药卫生—肿瘤]